system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Female, Humans, Kaplan-Meier Estimate, Male, Membrane Proteins, Middle Aged, Multivariate Analysis, Neoplasm Staging, Oncogene Proteins, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Young Adult.
user
Is elevated lysosome-associated protein transmembrane-4β-35 an independent prognostic marker in pancreatic carcinoma? Context: To investigate the relationship between lysosome-associated protein transmembrane-4β-35 (LAPTM4B-35) and the clinicopathological features and prognosis of pancreatic carcinoma. The level of LAPTM4B-35 protein was determined by semi quantitative immunohistochemistry  in pancreatic carcinoma specimens. The relationship between LAPTM4B-35 level and prognosis was determined using univariate and multivariate analyses. A total of 98 patient samples were included. The presence of LAPTM4B-35 protein was confirmed in 77/98 (78.6%) patients and was significantly  associated with tumour stage, degree of differentiation and pathological staging of pancreatic carcinoma after primary surgery. Patients with high LAPTM4B-35 levels had a poorer overall survival compared with patients with lower levels. Multivariate analysis showed that LAPTM4B-35 was an independent  prognostic factor for overall survival.
assistant
LAPTM4B-35 was found to be present at high levels in a large proportion of patients with pancreatic carcinoma, and was closely related to disease progression and poor prognosis. LAPTM4B-35 may represent a new molecular target for the clinical  evaluation and treatment of pancreatic carcinoma. Final Decision: yes